What is US 7,049,320 about?
US 7,049,320 is a U.S. patent document that concerns rolapitant (sold as Varubi), an antiemetic used to help prevent nausea and vomiting related to chemotherapy. [1]
Is rolapitant covered by this patent—and who uses it?
Rolapitant is a NK1 (neurokinin-1) receptor antagonist used in oncology supportive care. Patents like US 7,049,320 typically cover specific aspects such as the drug substance, formulations, or methods of use (for example, preventing chemotherapy-induced nausea and vomiting). [1]
How can I find the exact claims or the patent holder for US 7,049,320?
To verify exactly what US 7,049,320 claims (drug form, dosing regimen, method of treatment, or manufacturing details) and who the assignee is, you need to open the record and read the “Claims” and “Assignee/Inventor” sections on the patent page. [1]
When does this kind of patent expire?
Patent life depends on filing date, whether there were priority claims, and any term adjustments or extensions. The specific expiration date for US 7,049,320 must be checked on the patent record (or via the USPTO Patent Center). [1]
Where can I read US 7,049,320 online?
You can view the full text and metadata (including claims, inventors, and legal status) here: [1]
Sources
1. US 7,049,320 — Google Patents